Arcutis Biotherapeutics vs Zai Lab
ARQT and ZLAB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARQT and ZLAB compare
Zai Lab is the larger company, worth 11 times as much as Arcutis Biotherapeutics ($38.2B against $3.6B).
Arcutis Biotherapeutics grew revenue faster over the last twelve months (60.0% versus 0.02% for Zai Lab).
Arcutis Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of 5.9% compared with −44.9% at Zai Lab.
Arcutis Biotherapeutics scores higher on the StockData Score (11 against 6 for Zai Lab), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARQT | ZLAB |
|---|---|---|
| Size and price | ||
| Market cap | $3.6B | $38.2B |
| Share price | $28.26 | $24.60 |
| Change, 1 year | 20.5% | 12.4% |
| Change, 5 years | 55.4% | −70.8% |
| Beta (5Y) | 0.92 | 1.10 |
| Employees | 354 | 1,784 |
| StockData Score | ||
| Total score | 11 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 1 |
| Performance score | 4 (better) | 3 |
| Health score | 3 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 128× | – |
| P/S | 7.0× (better) | 86.5× |
| P/B | 14.6× (better) | 67.8× |
| EV/EBITDA | 96.7× | – |
| P/FCF | 59.5× | – |
| FCF yield | 1.7% (better) | −0.43% |
| Fair value | $6.04 | $4.31 |
| Margin of safety | −368% (better) | −471% |
| Growth | ||
| Revenue growth (TTM) | 60.0% (better) | 0.02% |
| Revenue growth, 5Y average | – | 56.5% |
| Profitability | ||
| Gross margin | 91.2% (better) | 54.7% |
| Operating margin | 6.9% (better) | −63.0% |
| Net margin | 5.9% (better) | −44.9% |
| FCF margin | 11.7% (better) | −37.0% |
| Return on equity | 14.9% (better) | −30.0% |
| Return on invested capital | 32.9% (better) | −87.6% |
| Financial health | ||
| Debt / equity | 0.45 | 0.45 (better) |
| Net debt / EBITDA | −4.27 | – |
| Interest coverage | 2.6× (better) | −45.2× |
| Current ratio | 2.92 (better) | 2.04 |
| Altman Z-score | 6.54 | 46.02 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 105% | 2.8% |
| Held by insiders | 9.3% | 0.67% |
| Insider net buying, 12 months | −$11.1M | −$10.8M (better) |
| Short interest, % of float | 15.9% | – |
Go deeper
- ARQT stock overview
- ARQT income statement
- ARQT valuation and score
- ZLAB stock overview
- ZLAB income statement
- ZLAB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.